Speaker Profile
Ph.D., Chief Scientific Officer, Nucleix
Biography
Dr. Catherine Schnabel brings over 20 years of scientific and leadership experience in the biomedical and molecular diagnostics industries. Prior to joining Nucleix, Cathy was the Chief Scientific Officer of Biotheranostics, where she led the development and translation of proprietary molecular signatures for breast cancer and metastatic disease, including incorporation of these novel technologies into clinical practice guidelines. An industry leader in evidencebased diagnostics, she has authored over 100 peerreviewed publications and disclosures and is an inventor on several patents. Cathy previously held research positions at Genentech, Genoptix and Amylin Pharmaceuticals, where she investigated and launched firstinclass therapies and biomarkers. Cathy holds a Ph.D. in cell and developmental biology from the Center for Advanced Biotechnology and Medicine at Rutgers University and was a fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University.
Talk
Epigenetic detection of early stage lung cancer
Nucleix will demonstrate the strength of its technology and differentiated approach to detecting cancer earlier to benefit physicians and patients, share results from the EpiCheck Lung Cancer Atlas, provide an update on its Sightline clinical study, which is currently enrolling 5,000 highrisk current and former smokers and share initial performance data for Lung EpiCheck.
Clinical Dx Showcase:
Nucleix
Nucleix is a liquid biopsy company revolutionizing early cancer detection and recurrence monitoring through the Company’s pioneering methylation based EpiCheck® technology. Construction of its Lung Cancer Atlas focuses on stage I disease to provide a high-resolution platform to discover novel, multi-omic biomarkers for cancer screening.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
